Back to Search
Start Over
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.
- Source :
-
Actas urologicas espanolas [Actas Urol Esp (Engl Ed)] 2023 Mar; Vol. 47 (2), pp. 111-126. Date of Electronic Publication: 2023 Jan 28. - Publication Year :
- 2023
-
Abstract
- Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone therapies (abiraterone, apalutamide, or enzalutamide) improves overall survival and is currently the standard of care. However, the decision on the specific regimen to accompany ADT should be discussed with the patient, considering factors such as possible associated toxicities, duration of treatment, comorbidities, patient preferences, as there is no sufficient evidence to recommend one regimen over the other in most cases. This paper summarizes the evidence on the management of mHSPC and provides consensus recommendations on the optimal treatment in combination with ADT in mHSPC patients, with special attention to the patient's clinical profile.<br /> (Copyright © 2023 AEU. Published by Elsevier España, S.L.U. All rights reserved.)
Details
- Language :
- English; Spanish; Castilian
- ISSN :
- 2173-5786
- Volume :
- 47
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Actas urologicas espanolas
- Publication Type :
- Academic Journal
- Accession number :
- 36720305
- Full Text :
- https://doi.org/10.1016/j.acuroe.2022.12.004